Special Issue "Role and Molecular Mechanism of Inhibitors in Cancers"
Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 1580
Cancer is major global health burden requiring innovative therapeutic strategies to help to circumvent death. Traditional treatments include surgery and non-specific chemotherapy to reduce tumor burden. With recent advances in cancer genomics and proteomics, multiple driver oncogenes have been identified and targeted successfully, most notably members of the kinase family involved in various cell signaling events. Furthermore, advances in antibody and small-molecule-based drug discovery have led to the development of multiple inhibitors for various cancer-related proteins. Recent advances in cancer immunotherapy have also helped to provide patients with unique therapeutic options to treat multiple types of cancer. Going forward, the field of cancer therapeutics will need to heavily rely on individual patient tumor genomic and proteomic profiles to deduce which therapeutic regimens would be most effective in this era of personalized medicine.
This Special Issue will summarize the role and molecular mechanisms of currently available inhibitors involved in treating various types of cancers. The use of small molecules and biologics as potential therapies to prevent or treat the progression of cancer will also be addressed.
Dr. Punit Saraon
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug discovery
- tumor suppressors
- cell signaling
- small molecules
- kinase inhibitors
- protein–protein interactions